CN114805398A - Preparation method of ecteinascidin compound - Google Patents
Preparation method of ecteinascidin compound Download PDFInfo
- Publication number
- CN114805398A CN114805398A CN202210038224.6A CN202210038224A CN114805398A CN 114805398 A CN114805398 A CN 114805398A CN 202210038224 A CN202210038224 A CN 202210038224A CN 114805398 A CN114805398 A CN 114805398A
- Authority
- CN
- China
- Prior art keywords
- benzoquinone
- acid
- compound
- membered
- formula
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- -1 ecteinascidin compound Chemical class 0.000 title claims description 111
- 229960000977 trabectedin Drugs 0.000 title claims description 20
- 238000002360 preparation method Methods 0.000 title claims description 16
- 238000000034 method Methods 0.000 claims abstract description 26
- PKVRCIRHQMSYJX-AIFWHQITSA-N trabectedin Chemical class C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 PKVRCIRHQMSYJX-AIFWHQITSA-N 0.000 claims abstract description 20
- 150000001875 compounds Chemical class 0.000 claims description 44
- 125000003118 aryl group Chemical group 0.000 claims description 33
- 125000004122 cyclic group Chemical group 0.000 claims description 26
- 125000001072 heteroaryl group Chemical group 0.000 claims description 24
- 125000004432 carbon atom Chemical group C* 0.000 claims description 23
- 229910052736 halogen Inorganic materials 0.000 claims description 23
- 150000002367 halogens Chemical class 0.000 claims description 23
- 229910052739 hydrogen Inorganic materials 0.000 claims description 23
- 239000001257 hydrogen Substances 0.000 claims description 23
- 125000006700 (C1-C6) alkylthio group Chemical group 0.000 claims description 17
- PXQLVRUNWNTZOS-UHFFFAOYSA-N sulfanyl Chemical class [SH] PXQLVRUNWNTZOS-UHFFFAOYSA-N 0.000 claims description 16
- JIAARYAFYJHUJI-UHFFFAOYSA-L zinc dichloride Chemical class [Cl-].[Cl-].[Zn+2] JIAARYAFYJHUJI-UHFFFAOYSA-L 0.000 claims description 16
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical class OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 claims description 15
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 claims description 14
- 239000003054 catalyst Substances 0.000 claims description 14
- 150000002431 hydrogen Chemical class 0.000 claims description 13
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 12
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 12
- 239000002253 acid Substances 0.000 claims description 11
- 125000004184 methoxymethyl group Chemical group [H]C([H])([H])OC([H])([H])* 0.000 claims description 11
- XXPXYPLPSDPERN-UHFFFAOYSA-N Ecteinascidin 743 Natural products COc1cc2C(NCCc2cc1O)C(=O)OCC3N4C(O)C5Cc6cc(C)c(OC)c(O)c6C(C4C(S)c7c(OC(=O)C)c(C)c8OCOc8c37)N5C XXPXYPLPSDPERN-UHFFFAOYSA-N 0.000 claims description 10
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 10
- 235000010233 benzoic acid Nutrition 0.000 claims description 10
- 239000005711 Benzoic acid Chemical class 0.000 claims description 9
- 229940092714 benzenesulfonic acid Drugs 0.000 claims description 9
- NADHCXOXVRHBHC-UHFFFAOYSA-N 2,3-dimethoxycyclohexa-2,5-diene-1,4-dione Chemical compound COC1=C(OC)C(=O)C=CC1=O NADHCXOXVRHBHC-UHFFFAOYSA-N 0.000 claims description 8
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical group Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 claims description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 8
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical class OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 claims description 8
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 8
- 239000011592 zinc chloride Chemical class 0.000 claims description 8
- 235000005074 zinc chloride Nutrition 0.000 claims description 8
- 125000006239 protecting group Chemical group 0.000 claims description 7
- 239000002841 Lewis acid Substances 0.000 claims description 6
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical class Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 claims description 6
- WTEOIRVLGSZEPR-UHFFFAOYSA-N boron trifluoride Chemical class FB(F)F WTEOIRVLGSZEPR-UHFFFAOYSA-N 0.000 claims description 6
- 150000007517 lewis acids Chemical class 0.000 claims description 6
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 claims description 5
- NOUZOVBGCDDMSX-UHFFFAOYSA-N 3,5-ditert-butylcyclohexa-3,5-diene-1,2-dione Chemical compound CC(C)(C)C1=CC(=O)C(=O)C(C(C)(C)C)=C1 NOUZOVBGCDDMSX-UHFFFAOYSA-N 0.000 claims description 5
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 claims description 5
- 150000008107 benzenesulfonic acids Chemical class 0.000 claims description 5
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 5
- ZEGDFCCYTFPECB-UHFFFAOYSA-N 2,3-dimethoxy-1,4-benzoquinone Natural products C1=CC=C2C(=O)C(OC)=C(OC)C(=O)C2=C1 ZEGDFCCYTFPECB-UHFFFAOYSA-N 0.000 claims description 4
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 claims description 4
- RMMPZDDLWLALLJ-UHFFFAOYSA-N Thermophillin Chemical compound COC1=CC(=O)C(OC)=CC1=O RMMPZDDLWLALLJ-UHFFFAOYSA-N 0.000 claims description 4
- 229910000147 aluminium phosphate Inorganic materials 0.000 claims description 4
- 150000001559 benzoic acids Chemical class 0.000 claims description 4
- 229910017604 nitric acid Inorganic materials 0.000 claims description 4
- 235000006408 oxalic acid Nutrition 0.000 claims description 4
- ITMCEJHCFYSIIV-UHFFFAOYSA-N triflic acid Chemical class OS(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-N 0.000 claims description 4
- 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 3
- 229910021630 Antimony pentafluoride Inorganic materials 0.000 claims description 3
- 229910015900 BF3 Inorganic materials 0.000 claims description 3
- VBVBHWZYQGJZLR-UHFFFAOYSA-I antimony pentafluoride Chemical class F[Sb](F)(F)(F)F VBVBHWZYQGJZLR-UHFFFAOYSA-I 0.000 claims description 3
- ORTQZVOHEJQUHG-UHFFFAOYSA-L copper(II) chloride Chemical class Cl[Cu]Cl ORTQZVOHEJQUHG-UHFFFAOYSA-L 0.000 claims description 3
- SBTSVTLGWRLWOD-UHFFFAOYSA-L copper(ii) triflate Chemical class [Cu+2].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F SBTSVTLGWRLWOD-UHFFFAOYSA-L 0.000 claims description 3
- YHBDIEWMOMLKOO-UHFFFAOYSA-I pentachloroniobium Chemical class Cl[Nb](Cl)(Cl)(Cl)Cl YHBDIEWMOMLKOO-UHFFFAOYSA-I 0.000 claims description 3
- AHZJKOKFZJYCLG-UHFFFAOYSA-K trifluoromethanesulfonate;ytterbium(3+) Chemical class [Yb+3].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F AHZJKOKFZJYCLG-UHFFFAOYSA-K 0.000 claims description 3
- JPJIEXKLJOWQQK-UHFFFAOYSA-K trifluoromethanesulfonate;yttrium(3+) Chemical class [Y+3].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F JPJIEXKLJOWQQK-UHFFFAOYSA-K 0.000 claims description 3
- FTVLMFQEYACZNP-UHFFFAOYSA-N trimethylsilyl trifluoromethanesulfonate Chemical class C[Si](C)(C)OS(=O)(=O)C(F)(F)F FTVLMFQEYACZNP-UHFFFAOYSA-N 0.000 claims description 3
- NWONKYPBYAMBJT-UHFFFAOYSA-L zinc sulfate Chemical class [Zn+2].[O-]S([O-])(=O)=O NWONKYPBYAMBJT-UHFFFAOYSA-L 0.000 claims description 3
- 229960001763 zinc sulfate Drugs 0.000 claims description 3
- 229910000368 zinc sulfate Inorganic materials 0.000 claims description 3
- CITILBVTAYEWKR-UHFFFAOYSA-L zinc trifluoromethanesulfonate Chemical class [Zn+2].[O-]S(=O)(=O)C(F)(F)F.[O-]S(=O)(=O)C(F)(F)F CITILBVTAYEWKR-UHFFFAOYSA-L 0.000 claims description 3
- UPGCDKVJPIRNTG-VIHNCQKYSA-N (6r,6ar,7s,13r,14s,16r,20r)-6',8,14-trihydroxy-7',9-dimethoxy-4,10-dimethyl-19-oxo-3',4',6,7,12,13,14,16-octahydro-2'h,6ah-spiro[7,13-epimino-6,16-(epithiopropanooxymethano)[1,3]dioxolo[7,8]isoquino[3,2-b][3]benzazocine-20,1'-isoquinolin]-5-yl acetate Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](O)[C@@H](CC=3C4=C(O)C(OC)=C(C)C=3)N[C@@H]4[C@@H]21 UPGCDKVJPIRNTG-VIHNCQKYSA-N 0.000 claims description 2
- 150000004057 1,4-benzoquinones Chemical class 0.000 claims description 2
- YBGORPOETHYSFS-UHFFFAOYSA-N 2,3,5,6-tetraiodocyclohexa-2,5-diene-1,4-dione Chemical compound IC1=C(I)C(=O)C(I)=C(I)C1=O YBGORPOETHYSFS-UHFFFAOYSA-N 0.000 claims description 2
- USAYMJGCALIGIG-UHFFFAOYSA-N 2,3-dichlorocyclohexa-2,5-diene-1,4-dione Chemical compound ClC1=C(Cl)C(=O)C=CC1=O USAYMJGCALIGIG-UHFFFAOYSA-N 0.000 claims description 2
- SICUQMNNOGDZJM-UHFFFAOYSA-N 2,5-dibromo-3,6-dimethoxycyclohexa-2,5-diene-1,4-dione Chemical compound COC1=C(Br)C(=O)C(OC)=C(Br)C1=O SICUQMNNOGDZJM-UHFFFAOYSA-N 0.000 claims description 2
- GLLMIZVPZWPYGP-UHFFFAOYSA-N 2,5-dichloro-3,6-dioxocyclohexa-1,4-diene-1,4-dicarbonitrile Chemical compound ClC1=C(C#N)C(=O)C(Cl)=C(C#N)C1=O GLLMIZVPZWPYGP-UHFFFAOYSA-N 0.000 claims description 2
- XMTVIMLHAWZAAB-UHFFFAOYSA-N 2,5-diethoxycyclohexa-2,5-diene-1,4-dione Chemical compound CCOC1=CC(=O)C(OCC)=CC1=O XMTVIMLHAWZAAB-UHFFFAOYSA-N 0.000 claims description 2
- DDXYWFGBQZICBD-UHFFFAOYSA-N 2,6-di(propan-2-yl)cyclohexa-2,5-diene-1,4-dione Chemical compound CC(C)C1=CC(=O)C=C(C(C)C)C1=O DDXYWFGBQZICBD-UHFFFAOYSA-N 0.000 claims description 2
- NTZCFGZBDDCNHI-UHFFFAOYSA-N 2-phenylanthracene-9,10-dione Chemical compound C=1C=C2C(=O)C3=CC=CC=C3C(=O)C2=CC=1C1=CC=CC=C1 NTZCFGZBDDCNHI-UHFFFAOYSA-N 0.000 claims description 2
- CIDYIYSNDAJNGX-UHFFFAOYSA-N 2-phenylnaphthalene-1,4-dione Chemical compound O=C1C2=CC=CC=C2C(=O)C=C1C1=CC=CC=C1 CIDYIYSNDAJNGX-UHFFFAOYSA-N 0.000 claims description 2
- ULGBTKPILRLLKN-UHFFFAOYSA-N 3,4,5,6-tetramethylcyclohexa-3,5-diene-1,2-dione Chemical compound CC1=C(C)C(=O)C(=O)C(C)=C1C ULGBTKPILRLLKN-UHFFFAOYSA-N 0.000 claims description 2
- ZHHWHRBCPITADA-UHFFFAOYSA-N 3,4,6-trichloro-5-methylcyclohexa-3,5-diene-1,2-dione Chemical compound CC1=C(Cl)C(=O)C(=O)C(Cl)=C1Cl ZHHWHRBCPITADA-UHFFFAOYSA-N 0.000 claims description 2
- NDMGGAGKEJHZOA-UHFFFAOYSA-N 3,5-dimethylcyclohexa-3,5-diene-1,2-dione Chemical compound CC1=CC(=O)C(=O)C(C)=C1 NDMGGAGKEJHZOA-UHFFFAOYSA-N 0.000 claims description 2
- NGXHJLXTUYWSDS-UHFFFAOYSA-N 3,6-dimethyl-4,5-dimorpholin-4-ylcyclohexa-3,5-diene-1,2-dione Chemical compound C1COCCN1C1=C(C)C(=O)C(=O)C(C)=C1N1CCOCC1 NGXHJLXTUYWSDS-UHFFFAOYSA-N 0.000 claims description 2
- YVTHSEAGHVWWKH-UHFFFAOYSA-N 3,6-ditert-butyl-4,5-dichlorocyclohexa-3,5-diene-1,2-dione Chemical compound CC(C)(C)C1=C(Cl)C(Cl)=C(C(C)(C)C)C(=O)C1=O YVTHSEAGHVWWKH-UHFFFAOYSA-N 0.000 claims description 2
- OVJKTGBVWHWEQH-UHFFFAOYSA-N 3,6-ditert-butyl-4,5-difluorocyclohexa-3,5-diene-1,2-dione Chemical compound CC(C)(C)C1=C(F)C(F)=C(C(C)(C)C)C(=O)C1=O OVJKTGBVWHWEQH-UHFFFAOYSA-N 0.000 claims description 2
- GGIIPXBCNQBUMK-UHFFFAOYSA-N 3,6-ditert-butyl-4,5-dimethoxycyclohexa-3,5-diene-1,2-dione Chemical compound COC1=C(C(C)(C)C)C(=O)C(=O)C(C(C)(C)C)=C1OC GGIIPXBCNQBUMK-UHFFFAOYSA-N 0.000 claims description 2
- YYBNZCMLHZKAKV-UHFFFAOYSA-N 3,6-ditert-butylcyclohexa-3,5-diene-1,2-dione Chemical compound CC(C)(C)C1=CC=C(C(C)(C)C)C(=O)C1=O YYBNZCMLHZKAKV-UHFFFAOYSA-N 0.000 claims description 2
- UMDWCIVEFBTXFU-UHFFFAOYSA-N 3-phenylnaphthalene-1,2-dione Chemical compound O=C1C(=O)C2=CC=CC=C2C=C1C1=CC=CC=C1 UMDWCIVEFBTXFU-UHFFFAOYSA-N 0.000 claims description 2
- HDEXQZFQDZGFLQ-UHFFFAOYSA-N 4,5-dibromo-3,6-dioxocyclohexa-1,4-diene-1,2-dicarbonitrile Chemical compound BrC1=C(Br)C(=O)C(C#N)=C(C#N)C1=O HDEXQZFQDZGFLQ-UHFFFAOYSA-N 0.000 claims description 2
- DJWWJQIYHOGNLM-UHFFFAOYSA-N 4,5-diethoxycyclohexa-3,5-diene-1,2-dione Chemical compound CCOC1=CC(=O)C(=O)C=C1OCC DJWWJQIYHOGNLM-UHFFFAOYSA-N 0.000 claims description 2
- RHQYTQNDPWDVOR-UHFFFAOYSA-N 4,5-diiodo-3,6-dioxocyclohexa-1,4-diene-1,2-dicarbonitrile Chemical compound IC1=C(I)C(=O)C(C#N)=C(C#N)C1=O RHQYTQNDPWDVOR-UHFFFAOYSA-N 0.000 claims description 2
- DBLIKIDSKOWTLF-UHFFFAOYSA-N 4,5-dimethoxy-3,6-diphenylcyclohexa-3,5-diene-1,2-dione Chemical compound COC=1C(OC)=C(C=2C=CC=CC=2)C(=O)C(=O)C=1C1=CC=CC=C1 DBLIKIDSKOWTLF-UHFFFAOYSA-N 0.000 claims description 2
- DCNHYWSNHGOKHN-UHFFFAOYSA-N 4,5-dimethoxycyclohexa-3,5-diene-1,2-dione Chemical compound COC1=CC(=O)C(=O)C=C1OC DCNHYWSNHGOKHN-UHFFFAOYSA-N 0.000 claims description 2
- JXGRPCUCLTUSGR-UHFFFAOYSA-N 4,6-dichloro-2,5-dioxocyclohexa-3,6-diene-1,3-dicarbonitrile Chemical compound ClC1=C(C#N)C(=O)C(C#N)=C(Cl)C1=O JXGRPCUCLTUSGR-UHFFFAOYSA-N 0.000 claims description 2
- ZKRLBHOGMYNZBH-UHFFFAOYSA-N 4,6-ditert-butyl-3-chlorocyclohexa-3,5-diene-1,2-dione Chemical compound CC(C)(C)C1=CC(C(C)(C)C)=C(Cl)C(=O)C1=O ZKRLBHOGMYNZBH-UHFFFAOYSA-N 0.000 claims description 2
- YDYHFBSKZVOOSR-UHFFFAOYSA-N 4-phenylnaphthalene-1,2-dione Chemical compound C12=CC=CC=C2C(=O)C(=O)C=C1C1=CC=CC=C1 YDYHFBSKZVOOSR-UHFFFAOYSA-N 0.000 claims description 2
- WZJTXQRITQYKKG-UHFFFAOYSA-N 4-tert-butylcyclohexa-3,5-diene-1,2-dione Chemical compound CC(C)(C)C1=CC(=O)C(=O)C=C1 WZJTXQRITQYKKG-UHFFFAOYSA-N 0.000 claims description 2
- YMAUZYADYYYPHZ-UHFFFAOYSA-N Ecteinascidin 770 Natural products COc1cc2C(NCCc2cc1O)C(=O)OCC3N4C(C#N)C5Cc6cc(C)c(OC)c(O)c6C(C4C(S)c7c(OC(=O)C)c(C)c8OCOc8c37)N5C YMAUZYADYYYPHZ-UHFFFAOYSA-N 0.000 claims description 2
- MNYMSPWCUHLLOZ-UHFFFAOYSA-N ecteinascidin 729 Natural products COc1cc2C(NCCc2cc1O)C(=O)OCC3N4C(O)C5Cc6cc(C)c(OC)c(O)c6C(N5)C4C(S)c7c(OC(=O)C)c(C)c8OCOc8c37 MNYMSPWCUHLLOZ-UHFFFAOYSA-N 0.000 claims description 2
- DZGBXOVHGNYJRY-KBVPHHNESA-N ecteinascidin 745 Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2C[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 DZGBXOVHGNYJRY-KBVPHHNESA-N 0.000 claims description 2
- NUTRSNLIZVBHBZ-UHFFFAOYSA-N ecteinascidin 745 Natural products C1=C(O)C(OC)=CC2=C1CCNC2(C(OC1)=O)CSC2C3=C(OC(C)=O)C(C)=C4OCOC4=C3C1N1CC(CC=3C4=C(O)C(OC)=C(C)C=3)NC4C12 NUTRSNLIZVBHBZ-UHFFFAOYSA-N 0.000 claims description 2
- UXTFBUVODQNPJE-UHFFFAOYSA-N ecteinascidin 759B Natural products C1=C(O)C(OC)=CC2=C1CCNC2(C(OC1)=O)CS(=O)C2C3=C(OC(C)=O)C(C)=C4OCOC4=C3C1N1C(O)C(CC=3C4=C(O)C(OC)=C(C)C=3)N(C)C4C12 UXTFBUVODQNPJE-UHFFFAOYSA-N 0.000 claims description 2
- BGFXHQYUWCGGLL-QWIBJBKUSA-N ecteinascidin 770 Chemical compound C([C@@]1(C(OC2)=O)NCCC3=C1C=C(C(=C3)O)OC)S[C@@H]1C3=C(OC(C)=O)C(C)=C4OCOC4=C3[C@H]2N2[C@@H](C#N)[C@H](CC=3C4=C(O)C(OC)=C(C)C=3)N(C)[C@H]4[C@@H]21 BGFXHQYUWCGGLL-QWIBJBKUSA-N 0.000 claims description 2
- 125000004008 6 membered carbocyclic group Chemical group 0.000 claims 2
- FBAFATDZDUQKNH-UHFFFAOYSA-M iron chloride Chemical class [Cl-].[Fe] FBAFATDZDUQKNH-UHFFFAOYSA-M 0.000 claims 2
- ZMLPZCGHASSGEA-UHFFFAOYSA-M zinc trifluoromethanesulfonate Chemical class [Zn+2].[O-]S(=O)(=O)C(F)(F)F ZMLPZCGHASSGEA-UHFFFAOYSA-M 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 abstract description 22
- 238000009776 industrial production Methods 0.000 abstract description 3
- 125000000623 heterocyclic group Chemical group 0.000 description 41
- 125000000217 alkyl group Chemical group 0.000 description 28
- 125000000753 cycloalkyl group Chemical group 0.000 description 27
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 16
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 14
- 125000003545 alkoxy group Chemical group 0.000 description 13
- 125000006413 ring segment Chemical group 0.000 description 12
- 125000002619 bicyclic group Chemical group 0.000 description 11
- 125000003367 polycyclic group Chemical group 0.000 description 11
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 9
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 9
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 8
- 125000003342 alkenyl group Chemical group 0.000 description 8
- 229910052799 carbon Inorganic materials 0.000 description 8
- 125000000304 alkynyl group Chemical group 0.000 description 7
- 229910052757 nitrogen Inorganic materials 0.000 description 7
- 125000003282 alkyl amino group Chemical group 0.000 description 6
- 125000004414 alkyl thio group Chemical group 0.000 description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 description 6
- 150000007942 carboxylates Chemical class 0.000 description 6
- 125000004093 cyano group Chemical group *C#N 0.000 description 6
- 125000000000 cycloalkoxy group Chemical group 0.000 description 6
- 125000005366 cycloalkylthio group Chemical group 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 239000003814 drug Substances 0.000 description 6
- 125000002950 monocyclic group Chemical group 0.000 description 6
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 6
- 125000001424 substituent group Chemical group 0.000 description 6
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 5
- 229940125904 compound 1 Drugs 0.000 description 5
- 125000000592 heterocycloalkyl group Chemical group 0.000 description 5
- 229910052760 oxygen Inorganic materials 0.000 description 5
- 239000001301 oxygen Substances 0.000 description 5
- HZNVUJQVZSTENZ-UHFFFAOYSA-N 2,3-dichloro-5,6-dicyano-1,4-benzoquinone Chemical compound ClC1=C(Cl)C(=O)C(C#N)=C(C#N)C1=O HZNVUJQVZSTENZ-UHFFFAOYSA-N 0.000 description 4
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 4
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 125000003003 spiro group Chemical group 0.000 description 4
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 4
- AZQWKYJCGOJGHM-UHFFFAOYSA-N 1,4-benzoquinone Chemical compound O=C1C=CC(=O)C=C1 AZQWKYJCGOJGHM-UHFFFAOYSA-N 0.000 description 3
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 206010039491 Sarcoma Diseases 0.000 description 3
- 208000021712 Soft tissue sarcoma Diseases 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- 125000004450 alkenylene group Chemical group 0.000 description 3
- 125000004429 atom Chemical group 0.000 description 3
- 125000002837 carbocyclic group Chemical group 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 125000005842 heteroatom Chemical group 0.000 description 3
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 3
- 125000004043 oxo group Chemical group O=* 0.000 description 3
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 3
- 125000003226 pyrazolyl group Chemical group 0.000 description 3
- 239000000126 substance Substances 0.000 description 3
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 3
- 125000000335 thiazolyl group Chemical group 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- 125000005918 1,2-dimethylbutyl group Chemical group 0.000 description 2
- FRASJONUBLZVQX-UHFFFAOYSA-N 1,4-naphthoquinone Chemical compound C1=CC=C2C(=O)C=CC(=O)C2=C1 FRASJONUBLZVQX-UHFFFAOYSA-N 0.000 description 2
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 125000004493 2-methylbut-1-yl group Chemical group CC(C*)CC 0.000 description 2
- 125000005916 2-methylpentyl group Chemical group 0.000 description 2
- 125000003542 3-methylbutan-2-yl group Chemical group [H]C([H])([H])C([H])(*)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 2
- 125000005917 3-methylpentyl group Chemical group 0.000 description 2
- KZMGYPLQYOPHEL-UHFFFAOYSA-N Boron trifluoride etherate Chemical compound FB(F)F.CCOCC KZMGYPLQYOPHEL-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 description 2
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 238000004440 column chromatography Methods 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 125000002883 imidazolyl group Chemical group 0.000 description 2
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 2
- 125000004491 isohexyl group Chemical group C(CCC(C)C)* 0.000 description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- VLKZOEOYAKHREP-UHFFFAOYSA-N methyl pentane Natural products CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000012074 organic phase Substances 0.000 description 2
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- 125000003386 piperidinyl group Chemical group 0.000 description 2
- 125000000714 pyrimidinyl group Chemical group 0.000 description 2
- 125000000719 pyrrolidinyl group Chemical group 0.000 description 2
- 229920006395 saturated elastomer Polymers 0.000 description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- SFLSHLFXELFNJZ-QMMMGPOBSA-N (-)-norepinephrine Chemical compound NC[C@H](O)C1=CC=C(O)C(O)=C1 SFLSHLFXELFNJZ-QMMMGPOBSA-N 0.000 description 1
- 125000004178 (C1-C4) alkyl group Chemical class 0.000 description 1
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 1
- 229940005561 1,4-benzoquinone Drugs 0.000 description 1
- 125000003660 2,3-dimethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003764 2,4-dimethylpentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000003229 2-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- JWUJQDFVADABEY-UHFFFAOYSA-N 2-methyltetrahydrofuran Chemical compound CC1CCCO1 JWUJQDFVADABEY-UHFFFAOYSA-N 0.000 description 1
- 125000004337 3-ethylpentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003469 3-methylhexyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 description 1
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- 125000003601 C2-C6 alkynyl group Chemical group 0.000 description 1
- 125000001313 C5-C10 heteroaryl group Chemical group 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- ZAFNJMIOTHYJRJ-UHFFFAOYSA-N Diisopropyl ether Chemical compound CC(C)OC(C)C ZAFNJMIOTHYJRJ-UHFFFAOYSA-N 0.000 description 1
- 241000798369 Ecteinascidia turbinata Species 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- 229910021578 Iron(III) chloride Inorganic materials 0.000 description 1
- SECXISVLQFMRJM-UHFFFAOYSA-N N-Methylpyrrolidone Chemical compound CN1CCCC1=O SECXISVLQFMRJM-UHFFFAOYSA-N 0.000 description 1
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 description 1
- 206010033128 Ovarian cancer Diseases 0.000 description 1
- 206010061535 Ovarian neoplasm Diseases 0.000 description 1
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 description 1
- BLRPTPMANUNPDV-UHFFFAOYSA-N Silane Chemical group [SiH4] BLRPTPMANUNPDV-UHFFFAOYSA-N 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 125000002777 acetyl group Chemical group [H]C([H])([H])C(*)=O 0.000 description 1
- 125000002252 acyl group Chemical group 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000005012 alkyl thioether group Chemical group 0.000 description 1
- 125000005233 alkylalcohol group Chemical group 0.000 description 1
- 125000004104 aryloxy group Chemical group 0.000 description 1
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 description 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 1
- 150000001602 bicycloalkyls Chemical group 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 description 1
- 230000024245 cell differentiation Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229940125782 compound 2 Drugs 0.000 description 1
- 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000002188 cycloheptatrienyl group Chemical group C1(=CC=CC=CC1)* 0.000 description 1
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000003678 cyclohexadienyl group Chemical group C1(=CC=CCC1)* 0.000 description 1
- 125000000596 cyclohexenyl group Chemical group C1(=CCCCC1)* 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000002433 cyclopentenyl group Chemical group C1(=CCCC1)* 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 description 1
- 125000004852 dihydrofuranyl group Chemical group O1C(CC=C1)* 0.000 description 1
- 125000005047 dihydroimidazolyl group Chemical group N1(CNC=C1)* 0.000 description 1
- 125000005052 dihydropyrazolyl group Chemical group N1(NCC=C1)* 0.000 description 1
- 125000005054 dihydropyrrolyl group Chemical group [H]C1=C([H])C([H])([H])C([H])([H])N1* 0.000 description 1
- 125000005448 ethoxyethyl group Chemical group [H]C([H])([H])C([H])([H])OC([H])([H])C([H])([H])* 0.000 description 1
- 229910052731 fluorine Inorganic materials 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 125000002485 formyl group Chemical group [H]C(*)=O 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000002632 imidazolidinyl group Chemical group 0.000 description 1
- 125000003392 indanyl group Chemical group C1(CCC2=CC=CC=C12)* 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- RBTARNINKXHZNM-UHFFFAOYSA-K iron trichloride Chemical compound Cl[Fe](Cl)Cl RBTARNINKXHZNM-UHFFFAOYSA-K 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 125000002757 morpholinyl group Chemical group 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001624 naphthyl group Chemical group 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229940000673 orphan drug Drugs 0.000 description 1
- 239000002859 orphan drug Substances 0.000 description 1
- 125000002971 oxazolyl group Chemical group 0.000 description 1
- 125000004193 piperazinyl group Chemical group 0.000 description 1
- FVSKHRXBFJPNKK-UHFFFAOYSA-N propionitrile Chemical compound CCC#N FVSKHRXBFJPNKK-UHFFFAOYSA-N 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 125000000547 substituted alkyl group Chemical group 0.000 description 1
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 125000001981 tert-butyldimethylsilyl group Chemical group [H]C([H])([H])[Si]([H])(C([H])([H])[H])[*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 125000000037 tert-butyldiphenylsilyl group Chemical group [H]C1=C([H])C([H])=C([H])C([H])=C1[Si]([H])([*]C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H])C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 description 1
- 125000003718 tetrahydrofuranyl group Chemical group 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 125000005958 tetrahydrothienyl group Chemical group 0.000 description 1
- 125000003831 tetrazolyl group Chemical group 0.000 description 1
- VLLMWSRANPNYQX-UHFFFAOYSA-N thiadiazole Chemical compound C1=CSN=N1.C1=CSN=N1 VLLMWSRANPNYQX-UHFFFAOYSA-N 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 125000000101 thioether group Chemical group 0.000 description 1
- 125000004568 thiomorpholinyl group Chemical group 0.000 description 1
- 125000000025 triisopropylsilyl group Chemical group C(C)(C)[Si](C(C)C)(C(C)C)* 0.000 description 1
- 239000008096 xylene Substances 0.000 description 1
- 229940004212 yondelis Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D515/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D515/22—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen, oxygen, and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains four or more hetero rings
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Abstract
The present disclosure relates to a method for preparing ecteinascidin compounds. The method has high yield and mild reaction conditions, and is suitable for industrial production.
Description
Technical Field
The disclosure belongs to the field of medicines, and relates to a preparation method of ecteinascidin compounds.
Background
Tribetidine (trade name Yondelis), developed by Qiangsheng pharmaceutical Co., Ltd., is a natural product isolated from the marine organism Ecteinascidia turbinata, but its content is extremely low, only 10 -6 ~10 -7 % w/w. Tributine was listed as a rare drug for soft tissue sarcoma in the European Union in 2001, and became the first modern marine drug. In 2004, the drug was classified by the U.S. Food and Drug Administration (FDA) as a rare drug for soft tissue sarcoma, and in europe and america, it was designated as an orphan drug for the treatment of acute lymphoblastic leukemia, soft tissue sarcoma, and ovarian cancer. Tribetidine can block tumorIn addition to the differentiation of cells in the G1/G2 cycle, the cells can also inhibit the secretion of Vascular Endothelial Growth Factor (VEGF) and the expression of its receptors. EP0309477B discloses a class of ecteinascidin compounds including ecteinascidins 729, 743 (trabectedin), 745, 759A, 759B and 770.
CN1096463C et al discloses a preparation method of trabectedin which compound 1 is a key intermediate, and among the methods disclosed in the current literature and patents, compound 1 is prepared by using the method of CN1096463C basically. In the reaction, very expensive N-methylpyridine carboxyformaldehyde needs to be added, and the addition amount is extremely excessive (20 equivalents are added in the patent), so that the whole process cost is extremely high, and the industrial production of the trabectedin is severely restricted.
Disclosure of Invention
The purpose of the present disclosure is to provide a novel method for preparing ecteinascidin compounds.
The disclosure provides a preparation method of a compound shown as a formula (I), which comprises the step of preparing a compound shown as a formula (IIA) by reacting a compound shown as a formula (II) in the presence of a benzoquinone compound and a catalyst,
wherein,
R 2 、R 3 、R 4 、R 5 Each independently selected from hydrogen and C 1 -C 6 Alkyl, 6-to 10-membered aryl、C 1 -C 6 Alkoxy radical, C 1 -C 6 Alkylthio, halogen, cyano, hydroxy, amino and mercapto, or, R 2 、R 3 Together with adjacent carbon atoms forming a ring system or R 3 、R 4 Together with adjacent carbon atoms forming a ring system or R 4 、R 5 Together with adjacent carbon atoms forming a ring system or R 2 、R 3 And R 4 、R 5 Taken together with the adjacent carbon atoms to form a ring system, each independently selected from the group consisting of carbocyclic, heterocyclic, aromatic and heteroaromatic rings, wherein the ring system is optionally substituted with C 1 -C 6 Alkyl radical, C 1 -C 6 Alkoxy radical, C 1 -C 6 Alkylthio, halogen, cyano, hydroxyl, amino and mercapto;
R 2 ’、R 3 ’、R 4 ’、R 5 ' each is independently selected from hydrogen, C 1 -C 6 Alkyl, 6-to 10-membered aryl, C 1 -C 6 Alkoxy radical, C 1 -C 6 Alkylthio, halogen, cyano, hydroxy, amino and mercapto, or, R 2 ’、R 3 ' together with the adjacent carbon atoms form a ring system or R 4 ’、R 5 ' together with the adjacent carbon atoms form a ring system or R 2 ’、R 3 ' and R 4 ’、R 5 ' taken together with adjacent carbon atoms form a ring system, each independently selected from the group consisting of carbocyclic, heterocyclic, aromatic and heteroaromatic rings, wherein said ring system is optionally substituted with C 1 -C 6 Alkyl radical, C 1 -C 6 Alkoxy radical, C 1 -C 6 Alkylthio, halogen, cyano, hydroxyl, amino and mercapto;
the catalyst is selected from protonic acid or Lewis acid;
R 1 、R 1 ’、R 1 "are each independently selected from hydrogen or a hydroxy protecting group;
ring B is selected fromWherein R is 2 、R 3 、R 4 、R 5 And R 2 ’、R 3 ’、R 4 ’、R 5 ' is consistent with the group selection in benzoquinone compounds. Said corresponding, e.g. benzoquinone, compound is selected fromThen ring B is selected from
In certain embodiments, R 2 、R 3 、R 4 、R 5 Each independently selected from hydrogen and C 1 -C 6 Alkyl radical, C 1 -C 6 Alkoxy radical, C 1 -C 6 Alkylthio, halogen, cyano, hydroxy, amino and mercapto.
In certain embodiments, R 2 ’、R 3 ’、R 4 ’、R 5 ' each is independently selected from hydrogen, C 1 -C 6 Alkyl radical, C 1 -C 6 Alkoxy radical, C 1 -C 6 Alkylthio, halogen, cyano, hydroxy, amino and mercapto.
Specific examples of benzoquinone-like compounds include, but are not limited to: DDQ (2, 3-dichloro-5, 6-dicyano-1, 4-benzoquinone); NQ (1, 4-naphthoquinone); TCQ (2, 3,4, 5-tetrachlorobenzoquinone); TBQ (2, 3,4, 5-tetrabromobenzoquinone); TFQ (2, 3,4, 5-tetrafluorobenzoquinone); BQ (1, 4-benzoquinone); 3, 6-di-tert-butyl-4, 5-dimethoxy-1, 2-benzoquinone; 3, 6-di-tert-butyl-4, 5-dichloro-1, 2-benzoquinone; 3, 6-di-tert-butyl-4, 5-difluoro-1, 2-benzoquinone; 3,4,5, 6-tetramethyl-1, 2-benzoquinone; 3,4,5, 6-tetraethyl-1, 2-benzoquinone; 3,4, 6-trichloro-5-methyl-1, 2-benzoquinone; 3, 6-diphenyl-4, 5-dimethoxy-1, 2-benzoquinone; 3, 6-dichloro-4, 5-dimethoxy-1, 2-benzoquinone; 3, 6-dimethyl-4, 5-dimorpholinyl-1, 2-benzoquinone; 3, 5-di-tert-butyl-1, 2-benzoquinone; 4, 5-dimethoxy-1, 2-benzoquinone; 4, 5-diethoxy-1, 2-benzoquinone; 3, 6-di-tert-butyl-1, 2-benzoquinone; 4-tert-butyl-1, 2-benzoquinone; 3, 5-dimethyl-1, 2-benzoquinone; 3, 5-di-tert-butyl-6-chloro-1, 2-benzoquinone; 4-phenylnaphthalene-1, 2-dione; 3-phenylnaphthalene-1, 2-dione; 2, 3-dimethoxy-1, 4 benzoquinone; 2, 6-diisopropyl-1, 4 benzoquinone; 2,3,5, 6-tetraiodo-1, 4 benzoquinone; 2, 5-dimethoxy-1, 4 benzoquinone; 2, 3-dimethoxy-1, 4 benzoquinone; 2, 3-dichloro-1, 4-benzoquinone; 2, 5-diethoxy-1, 4-benzoquinone; 2-phenyl-1, 4-naphthoquinone; 2-phenyl-anthraquinone; 2, 5-dibromo-3, 6-dimethoxy-1, 4-benzoquinone; 2, 3-dibromo-5, 6-dicyano-1, 4-benzoquinone; 2, 5-dichloro-3, 6-dicyano-1, 4-benzoquinone; 2, 6-dichloro-3, 5-dicyano-1, 4-benzoquinone; and 2, 3-diiodo-5, 6-dicyano-1, 4-benzoquinone, and the like.
Hydroxy protecting Groups are suitable Groups for hydroxy protection known in the art, see the literature ("Protective Groups in Organic Synthesis", 5) Th Ed.T.W.Greene&P.g.m.wuts). By way of example, the hydroxyl protecting group may preferably be (C) 1-10 Alkyl or aryl) 3 Silane groups, for example: triethylsilyl, triisopropylsilyl, tert-butyldimethylsilyl, tert-butyldiphenylsilyl and the like; may be C 1-10 Alkyl or substituted alkyl, preferably alkoxy or aryl substituted alkyl, more preferably C 1-6 Alkoxy-substituted C 1-6 Alkyl or phenyl substituted C 1-6 Alkyl, most preferably C 1-4 Alkoxy-substituted C 1-4 Alkyl groups, for example: methyl, t-butyl, allyl, benzyl, methoxymethyl (MOM), ethoxyethyl, 2-Tetrahydropyranyl (THP), and the like; may be (C) 1-10 Alkyl or aryl) acyl groups, such as: formyl, acetyl, benzoyl and the like; may be (C) 1-6 Alkyl or C 6-10 Aryl) sulfonyl; or (C) 1-6 Alkoxy or C 6-10 Aryloxy) carbonyl. In certain embodiments, the hydroxy protecting group is preferably methoxymethyl.
In certain embodiments, R 1 、R 1 ’、R 1 "are each independently selected from hydrogen, methoxymethyl, methoxyethoxymethyl, allyl or p-methoxybenzyl, preferably R 1 、R 1 ’、R 1 "is hydrogen, methoxymethyl, methoxyethoxymethyl or p-methoxybenzyl. .
The protic acid includes the commonly used inorganic and organic acids such as hydrochloric acid, acetic acid, sulfuric acid, nitric acid, phosphoric acid, oxalic acid, citric acid, benzenesulfonic acid, substituted benzenesulfonic acid, benzoic acid, substituted benzoic acid, trifluoroacetic acid, trifluoromethanesulfonic acid and the like.
Lewis acids include aluminum chloride, ferric chloride, boron trifluoride, antimony pentafluoride, niobium pentachloride, zinc chloride, copper chloride, zinc sulfate, zinc triflate, ytterbium triflate, yttrium triflate, copper triflate, TMSOTf, boron trifluoride etherate, and the like. In certain embodiments, the Lewis acid is selected from zinc chloride.
In certain embodiments, the molar ratio of the compound of formula (II) to the benzoquinone-like compound may be from 2:1 to 1:20, preferably from 1:1 to 1: 10.
In certain embodiments, the molar ratio of the compound of formula (II) to the catalyst may be from 1:0.1 to 1:1.5, preferably from 1:0.5 to 1:1.
The solvent used for the reaction may be a conventional solvent such as water, dimethylformamide, 1-methyl-2-pyrrolidone, tetrahydrofuran, methyltetrahydrofuran, dioxane, toluene, xylene, dimethyl sulfoxide, diethyl ether, isopropyl ether, methyl tert-butyl ether, acetonitrile, propionitrile, C 1 -C 6 One or more of alkyl alcohol, acetone, ethyl acetate, preferably methanol and/or tetrahydrofuran.
The reaction temperature of the reaction may be-20 ℃ to 200 ℃, preferably 0 ℃ to 150 ℃, more preferably 0 ℃ to 70 ℃.
In certain embodiments, the method further comprises the step of reacting the compound of formula (IIA) with an acid, including common inorganic and organic acids, including but not limited to hydrochloric acid, acetic acid, sulfuric acid, nitric acid, phosphoric acid, oxalic acid, citric acid, benzenesulfonic acid, substituted benzenesulfonic acids, benzoic acid, substituted benzoic acids, trifluoroacetic acid, trifluoromethanesulfonic acid, and the like. Substituted benzenesulfonic acid or benzoic acid means that benzenesulfonic acid or benzoic acid is selected from C 1 -C 6 Alkyl radical, C 1 -C 6 Alkoxy radical, C 1 -C 6 Alkylthio, halogen, cyano, hydroxyl and amino.
In certain embodiments, the molar ratio of the compound of formula (IIA) to the acid may be from 1:1 to 1: 100.
The solvent used for the reaction may be a conventional solvent. The reaction temperature of the reaction may be-20 ℃ to 200 ℃.
The disclosure also provides a preparation method of the compound shown as the formula (I), which comprises the step of reacting the compound shown as the formula (II) in the presence of a benzoquinone compound and a catalyst to prepare an intermediate compound, and the step of reacting the intermediate compound with an acid,
wherein,
R 2 、R 3 、R 4 、R 5 Each independently selected from hydrogen and C 1 -C 6 Alkyl, 6-to 10-membered aryl, C 1 -C 6 Alkoxy radical, C 1 -C 6 Alkylthio, halogen, cyano, hydroxy, amino and mercapto;
R 2 ’、R 3 ’、R 4 ’、R 5 ' Each is independently selected from hydrogen, C 1 -C 6 Alkyl, 6-to 10-membered aryl, C 1 -C 6 Alkoxy radical, C 1 -C 6 Alkylthio, halogen, cyano, hydroxy, amino and mercapto;
the catalyst is selected from protonic acid or Lewis acid;
R 1 、R 1 ' are each independently selected from hydrogen or a hydroxy protecting group.
The disclosure also provides a preparation method of the ecteinascidin compound, which comprises the preparation method of the compound shown in the formula (I).
The disclosure also provides a preparation method of the ecteinascidin compounds, which comprises a method for preparing the compounds shown in the formula (I) from the compounds shown in the formula (IIA) disclosed by the disclosure.
In certain embodiments, the ecteinascidin based compound is selected from one or more of ecteinascidin 729, trabectedin, ecteinascidin 745, ecteinascidin 759A, ecteinascidin 759B, and ecteinascidin 770.
In certain embodiments, the ecteinascidin compound is selected from the group consisting of trabectedin, and the method further comprises
In certain embodiments, R 1 Is methoxymethyl, the process further comprising
In certain embodiments, the ecteinascidin compound is selected from the group consisting of trabectedin, R 1 Is methoxymethyl, the process further comprising
In certain embodiments, the method further comprises
In certain embodiments, the ecteinascidin compound is selected from the group consisting of trabectedin, R 1 Is hydrogen, the process further comprising
The disclosure also provides a compound of formula (IIA),
in certain embodiments, R 1 "is hydrogen, methoxymethyl, methoxyethoxymethyl, allyl or p-methoxybenzyl.
In certain embodiments, the compound of formula (IIA) is
The disclosure also provides a preparation method of the compound shown in the formula (IIA), which comprises a method for preparing the compound shown in the formula (IIA) by reacting the compound shown in the formula (II) in the presence of a benzoquinone compound and a catalyst.
The preparation method of the ecteinascidin compound disclosed by the invention has the advantages of high reaction yield, mild reaction conditions, avoidance of use of expensive reagents, lower cost and suitability for industrial production.
The "alkyl" groups described in this disclosure are preferably C 1 -C 6 An alkyl group.
The "alkenyl" groups described in this disclosure are preferably C 2 -C 6 An alkenyl group.
The "alkynyl" groups described in this disclosure are preferably C 2 -C 6 Alkynyl.
The "alkylene" groups described in this disclosure are preferably C 1 -C 6 An alkylene group.
The "alkenylene" as described in the present disclosure is preferably C 2 -C 6 An alkenylene group.
"Alkenylene" as described in the present disclosure is preferably C 2 -C 6 Alkynylene radical.
The "alkoxy" groups described in this disclosure are preferably C 1 -C 6 An alkoxy group.
The "alkyl sulfide group" described in the present disclosure is preferably C 1 -C 6 An alkyl thioether group.
The "cycloalkyl" group described in the present disclosure is preferably a 3 to 12-membered, more preferably a 3 to 6-membered cycloalkyl group.
The "fused cycloalkyl" described in the present disclosure is preferably a 6 to 14-membered fused cycloalkyl, more preferably a 7 to 10-membered fused cycloalkyl.
The "heterocyclic group" described in the present disclosure is preferably a 3-to 12-membered, more preferably a 3-to 6-membered heterocyclic group.
The "fused heterocyclic group" described in the present disclosure is preferably a 6-to 14-membered fused heterocyclic group, more preferably a 7-to 10-membered fused heterocyclic group.
The "aryl" group described in the present disclosure is preferably a 6 to 14-membered, more preferably a 6 to 10-membered aryl group.
The "heteroaryl" group described in the present disclosure is preferably a 5-to 12-membered heteroaryl group, more preferably a 5-to 10-membered heteroaryl group.
Unless stated to the contrary, terms used in the specification and claims have the following meanings.
The term "alkyl" refers to a saturated aliphatic hydrocarbon group which is a straight or branched chain group containing 1 to 20 carbon atoms, preferably an alkyl group containing 1 to 12 carbon atoms. Non-limiting examples include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1-dimethylpropyl, 1, 2-dimethylpropyl, 2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1, 2-trimethylpropyl, 1-dimethylbutyl, 1, 2-dimethylbutyl, 2-dimethylbutyl, 1, 3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2, 3-dimethylbutyl, n-heptyl, 2-methylhexyl, 3-methylhexyl, 4-methylhexyl, 5-methylhexyl, 2, 3-dimethylpentyl, 2, 4-dimethylpentyl, 2-dimethylpentyl, 3-dimethylpentyl, 2-ethylpentyl, 3-ethylpentyl, n-octyl, 2, 3-dimethylhexyl, 2, 4-dimethylhexyl, 2, 5-dimethylhexyl, 2-dimethylhexyl, 3-dimethylhexyl, 4-dimethylhexyl, 2-ethylhexyl, 3-ethylhexyl, 4-ethylhexyl, 2-methyl-2-ethylpentyl, 2-methyl-3-ethylpentyl, n-nonyl, 2-methyl-2-ethylhexyl, 2-methyl-3-ethylhexyl, 2-dimethylpentyl, 2-dimethylhexyl, 3-dimethylpentyl, 2-ethylhexyl, 3-dimethylhexyl, 2-ethylhexyl, 2-dimethylhexyl, 2-ethylhexyl, 2-dimethylhexyl, 2-dimethylhexyl, 2-dimethylhexyl, 2-ethylhexyl, 2-ethyl, 2-2, 2-2, 2-2, or, 2, 2-diethylpentyl, n-decyl, 3-diethylhexyl, 2-diethylhexyl, and various branched isomers thereof. More preferred are lower alkyl groups having 1 to 6 carbon atoms, non-limiting examples of which include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, sec-butyl, n-pentyl, 1-dimethylpropyl, 1, 2-dimethylpropyl, 2-dimethylpropyl, 1-ethylpropyl, 2-methylbutyl, 3-methylbutyl, n-hexyl, 1-ethyl-2-methylpropyl, 1, 2-trimethylpropyl, 1-dimethylbutyl, 1, 2-dimethylbutyl, 2-dimethylbutyl, 1, 3-dimethylbutyl, 2-ethylbutyl, 2-methylpentyl, 3-methylpentyl, 4-methylpentyl, 2, 3-dimethylbutyl and the like. The alkyl group may be substituted or unsubstituted, and when substituted, the substituent may be substituted at any available point of attachment, preferably one or more groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halo, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, oxo, carboxy or carboxylate.
The term "alkoxy" refers to-O- (alkyl) and-O- (unsubstituted cycloalkyl), wherein alkyl is as defined above. Non-limiting examples of alkoxy groups include: methoxy, ethoxy, propoxy, butoxy, cyclopropoxy, cyclobutoxy, cyclopentyloxy, cyclohexyloxy. Alkoxy groups may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocyclyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, carboxy or carboxylate groups.
The term "halogen" refers to fluorine, chlorine, bromine or iodine.
The term "cycloalkyl" refers to a saturated or partially unsaturated monocyclic or polycyclic cyclic hydrocarbon substituent, the cycloalkyl ring containing from 3 to 20 carbon atoms, preferably from 3 to 12 carbon atoms, more preferably from 3 to 6 carbon atoms. Non-limiting examples of monocyclic cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclopentenyl, cyclohexyl, cyclohexenyl, cyclohexadienyl, cycloheptyl, cycloheptatrienyl, cyclooctyl, and the like; polycyclic cycloalkyl groups include spiro, fused and bridged cycloalkyl groups. "carbocyclic" refers to a ring system in a cycloalkyl group.
The term "spirocycloalkyl" refers to a 5 to 20 membered polycyclic group sharing one carbon atom (referred to as a spiro atom) between monocyclic rings, which may contain one or more double bonds, but none of the rings have a completely conjugated pi-electron system. Preferably 6 to 14, more preferably 7 to 10. Spirocycloalkyl groups are classified into a single spirocycloalkyl group, a double spirocycloalkyl group or a multi spirocycloalkyl group, preferably a single spirocycloalkyl group and a double spirocycloalkyl group, according to the number of spiro atoms shared between rings. More preferably 4-membered/4-membered, 4-membered/5-membered, 4-membered/6-membered, 5-membered/5-membered or 5-membered/6-membered. "spirocarbocycle" refers to a ring system in a spirocycloalkyl group. Non-limiting examples of spirocycloalkyl groups include:
the term "fused cyclic alkyl" refers to a 5 to 20 membered all carbon polycyclic group in which each ring in the system shares an adjacent pair of carbon atoms with other rings in the system, wherein one or more of the rings may contain one or more double bonds, but none of the rings has a completely conjugated pi-electron system. Preferably 6 to 14, more preferably 7 to 10. They may be classified into bicyclic, tricyclic, tetracyclic or polycyclic fused ring alkyls according to the number of constituent rings, preferably bicyclic or tricyclic, more preferably 5-or 6-membered bicycloalkyl. "fused carbocycle" refers to a ring system within a fused ring alkyl group. Non-limiting examples of fused ring alkyl groups include:
the term "bridged cycloalkyl" refers to a 5 to 20 membered all carbon polycyclic group in which any two rings share two carbon atoms not directly attached, which may contain one or more double bonds, but none of the rings have a completely conjugated pi-electron system. Preferably 6 to 14, more preferably 7 to 10. They may be classified as bicyclic, tricyclic, tetracyclic or polycyclic bridged cycloalkyl groups, preferably bicyclic, tricyclic or tetracyclic, more preferably bicyclic or tricyclic, depending on the number of constituent rings. Non-limiting examples of bridged cycloalkyl groups include:
the cycloalkyl ring may be fused to an aryl, heteroaryl or heterocycloalkyl ring, where the ring to which the parent structure is attached is a cycloalkyl, non-limiting examples of which include indanyl, tetrahydronaphthyl, benzocycloheptanyl, and the like. Cycloalkyl groups may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, oxo, carboxy or carboxylate.
The term "heterocyclyl" refers to a saturated or partially unsaturated mono-or polycyclic cyclic hydrocarbon substituent containing from 3 to 20 ring atoms wherein one or more of the ring atoms is selected from nitrogen, oxygen, or S (O) m (wherein m is an integer from 0 to 2) but excludes the ring moiety of-O-O-, -O-S-, or-S-S-, the remaining ring atoms being carbon. Preferably 3 to 12 ring atoms, of which 1 to 4 are heteroatoms; more preferably from 3 to 6 ring atoms. Non-limiting examples of monocyclic heterocyclyl groups include pyrrolidinyl, imidazolidinyl, tetrahydrofuranyl, tetrahydrothienyl, dihydroimidazolyl, dihydrofuranyl, dihydropyrazolyl, dihydropyrrolyl, piperidinyl, piperazinyl, morpholinyl, thiomorpholinyl, homopiperazinyl, and the like, with piperidinyl, pyrrolidinyl being preferred. Polycyclic heterocyclic groups include spiro, fused and bridged heterocyclic groups. "heterocycle" refers to a ring system within a heterocyclyl.
The term "spiroheterocyclyl" refers to a 5-to 20-membered polycyclic heterocyclic group in which one atom (referred to as the spiro atom) is shared between monocyclic rings, and in which one or more ring atoms is selected from nitrogen, oxygen, or S (O) m (wherein m is an integer of 0 to 2),the remaining ring atoms are carbon. It may contain one or more double bonds, but no ring has a completely conjugated pi-electron system. Preferably 6 to 14, more preferably 7 to 10. The spiro heterocyclic group is classified into a mono-spiro heterocyclic group, a di-spiro heterocyclic group or a multi-spiro heterocyclic group, preferably a mono-spiro heterocyclic group and a di-spiro heterocyclic group, according to the number of spiro atoms shared between rings. More preferred are 4-membered/4-membered, 4-membered/5-membered, 4-membered/6-membered, 5-membered/5-membered or 5-membered/6-membered mono spiroheterocyclic groups. "Spiroheterocycle" refers to a ring system within a spiroheterocycle group. Non-limiting examples of spiro heterocyclic groups include:
the term "fused heterocyclyl" refers to a 5 to 20 membered polycyclic heterocyclic group in which each ring in the system shares an adjacent pair of atoms with other rings in the system, one or more rings may contain one or more double bonds, but none of the rings has a fully conjugated pi-electron system in which one or more ring atoms is selected from nitrogen, oxygen or S (O) m (wherein m is an integer of 0 to 2) and the remaining ring atoms are carbon. Preferably 6 to 14, more preferably 7 to 10. They may be classified into bicyclic, tricyclic, tetracyclic or polycyclic fused heterocyclic groups according to the number of constituent rings, preferably bicyclic or tricyclic, more preferably 5-or 6-membered bicyclic fused heterocyclic groups. "fused heterocycle" refers to a ring system within a fused heterocyclic group. Non-limiting examples of fused heterocyclic groups include:
the term "bridged heterocyclyl" refers to a 5 to 14 membered polycyclic heterocyclic group in which any two rings share two atoms not directly attached which may contain one or more double bonds, but none of the rings have a fully conjugated pi-electron system in which one or more of the ring atoms is selected from nitrogen, oxygen or S (O) m (wherein m is an integer of 0 to 2) and the remaining ring atoms are carbon. Preferably 6 to 14, more preferably 7 to 10. Depending on the number of component ringsTo be divided into bicyclic, tricyclic, tetracyclic or polycyclic bridged heterocyclic groups, preferably bicyclic, tricyclic or tetracyclic, more preferably bicyclic or tricyclic. Non-limiting examples of bridged heterocyclic groups include:
the heterocyclyl ring may be fused to an aryl, heteroaryl or cycloalkyl ring, wherein the ring to which the parent structure is attached is heterocyclyl, non-limiting examples of which include:
The heterocyclyl group may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, oxo, carboxy or carboxylate.
The term "aryl" refers to a 6 to 14 membered all carbon monocyclic or fused polycyclic (i.e., rings which share adjacent pairs of carbon atoms) group having a conjugated pi-electron system, preferably 6 to 10 membered, such as phenyl and naphthyl. The aryl ring may be fused to a heteroaryl, heterocyclyl or cycloalkyl ring, wherein the ring attached to the parent structure is an aryl ring. "aromatic ring" refers to a ring system in an aryl group. Non-limiting examples of aryl groups include:
the aryl group may be substituted or unsubstituted, and when substituted, the substituent is preferably one or more groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxy, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, carboxy or carboxylate, preferably phenyl.
The term "heteroaryl" refers to a heteroaromatic system comprising 1 to 4 heteroatoms, 5 to 14 ring atoms, wherein the heteroatoms are selected from oxygen, sulfur and nitrogen. Heteroaryl is preferably 5 to 12 membered, such as imidazolyl, furyl, thienyl, thiazolyl, pyrazolyl, oxazolyl, pyrrolyl, tetrazolyl, pyridyl, pyrimidinyl, thiadiazole, pyrazinyl and the like, preferably imidazolyl, pyrazolyl, pyrimidinyl or thiazolyl; more preferably pyrazolyl or thiazolyl. The heteroaryl ring may be fused to an aryl, heterocyclyl, or cycloalkyl ring, wherein the ring joined to the parent structure is a heteroaryl ring. "heteroaryl ring" refers to a ring system in a heteroaryl group. Non-limiting examples of heteroaryl groups include:
heteroaryl groups may be optionally substituted or unsubstituted, and when substituted, the substituents are preferably one or more groups independently selected from alkyl, alkenyl, alkynyl, alkoxy, alkylthio, alkylamino, halogen, mercapto, hydroxyl, nitro, cyano, cycloalkyl, heterocycloalkyl, aryl, heteroaryl, cycloalkoxy, heterocycloalkoxy, cycloalkylthio, heterocycloalkylthio, carboxyl or carboxylate groups.
"optional" or "optionally" means that the subsequently described event or circumstance may, but need not, occur, and that the description includes instances where the event or circumstance occurs or does not. For example, "a heterocyclic group optionally substituted with an alkyl" means that an alkyl may, but need not, be present, and the description includes the case where the heterocyclic group is substituted with an alkyl and the heterocyclic group is not substituted with an alkyl.
In the chemical structure of the compounds described in the present disclosure, a bondNot specifying a configuration, i.e.If configurational isomerism is present in the chemical structure, the bondCan be thatOrOr at the same time containAndtwo configurations. In the chemical structure of the compounds described in the present disclosure, a bondThe configuration is not specified, i.e., either the Z configuration or the E configuration, or both configurations are contemplated.
Detailed Description
The present disclosure will be explained in detail with reference to specific examples below so that those skilled in the art can more fully understand that the specific examples of the present disclosure are merely illustrative of the technical solutions of the present disclosure and do not limit the present disclosure in any way.
Example 1
20ml of tetrahydrofuran, 20ml of absolute methanol and 2g of the compound (2) were added to a reaction flask, and stirred to dissolve the mixture, 2.6g of 3, 5-di-tert-butyl-1, 2-benzoquinone and 0.4g of zinc chloride were added, and stirred under nitrogen to react and prepare an intermediate 2A. Then, the temperature was reduced to 10 ℃ and 20ml of a saturated oxalic acid solution was added. The temperature is raised to the room temperature, and the reaction is stirred until the reaction is finished. To a reaction flask were added 40ml of dichloromethane and 60ml of water, sodium bicarbonate was added to adjust the pH to 7-8, the phases were separated, the aqueous phase was extracted with dichloromethane, the organic phases were combined, washed with 25% sodium chloride, dried over anhydrous sodium sulfate, concentrated and purified by column chromatography (pure DCM to n-hexane: ethyl acetate ═ 2:1) to give compound 1(1.85g, 92%).
Example 2
200ml of tetrahydrofuran, 200ml of absolute methanol and 20g of the compound 2 were put into a reaction flask, stirred and dissolved, 26g of 3, 5-di-tert-butyl-1, 2-benzoquinone and 4g of zinc chloride were added, and stirred and reacted under nitrogen protection to prepare an intermediate 2A. Then, the temperature was reduced to 10 ℃ and 200ml of a saturated oxalic acid solution was added. Heating to 20-30 ℃, heating to room temperature, and stirring for reaction until the reaction is finished. To a reaction flask were added 400ml of dichloromethane and 600ml of water, sodium bicarbonate was added to adjust the pH to 7-8, the phases were separated, the aqueous phase was extracted with dichloromethane, the organic phases were combined, washed with 25% sodium chloride, dried over anhydrous sodium sulfate, concentrated and purified by column chromatography (pure DCM to n-hexane: ethyl acetate ═ 2:1) to give compound 1(19.12g, 95%).
Example 3
A total of 19g of Compound 1 was charged according to the method disclosed in CN1096463C to obtain 8g of trabectedin.
Example 4 reaction without addition of catalyst
According to the method of example 1, however, no zinc chloride was added during the reaction, and the same reaction conditions were used, and it was found by TLC that substantially no compound 2A was produced, indicating that the reaction was difficult to proceed without the addition of the catalyst.
Since the present disclosure has been described in terms of specific embodiments thereof, certain modifications and equivalent variations will be apparent to those skilled in the art and are intended to be included within the scope of the present disclosure.
Claims (14)
1. A preparation method of a compound shown as a formula (I) comprises the step of reacting a compound shown as a formula (II) in the presence of a benzoquinone compound and a catalyst to prepare a compound shown as a formula (IIA),
wherein,
R 2 、R 3 、R 4 、R 5 Each independently selected from hydrogen and C 1 -C 6 Alkyl, 6-to 10-membered aryl, C 1 -C 6 Alkoxy radical, C 1 -C 6 Alkylthio, halogen, cyano, hydroxy, amino and mercapto, or, R 2 、R 3 Together with adjacent carbon atoms forming a ring system or R 3 、R 4 Together with adjacent carbon atoms forming a ring system or R 4 、R 5 Together with adjacent carbon atoms forming a ring system or R 2 、R 3 And R 4 、R 5 Taken together with adjacent carbon atoms to form a ring system, each independently selected from a 3-to 6-membered carbocyclic ring, a 3-to 6-membered heterocyclic ring, a 6-to 10-membered aromatic ring, and a 5-to 10-membered heteroaromatic ring, wherein the ring system is optionally substituted with C 1 -C 6 Alkyl radical, C 1 -C 6 Alkoxy radical, C 1 -C 6 Alkylthio, halogen, cyano, hydroxyl, amino and mercapto;
R 2 ’、R 3 ’、R 4 ’、R 5 ' each is independently selected from hydrogen, C 1 -C 6 Alkyl, 6-to 10-membered aryl, C 1 -C 6 Alkoxy radical, C 1 -C 6 Alkylthio, halogen, cyano, hydroxy, amino and mercapto, or, R 2 ’、R 3 ' together with the adjacent carbon atoms form a ring system or R 4 ’、R 5 ' together with the adjacent carbon atoms form a ring system or R 2 ’、R 3 ' and R 4 ’、R 5 ' taken together with the adjacent carbon atoms to form a ring system, each independently selected from a 3-to 6-membered carbocyclic ring, a 3-to 6-membered heterocyclic ring, a 6-to 10-membered aromatic ring, and a 5-to 10-membered heteroaromatic ring, wherein the ring system is optionally substituted with a pharmaceutically acceptable carrierQuilt selection C 1 -C 6 Alkyl radical, C 1 -C 6 Alkoxy radical, C 1 -C 6 Alkylthio, halogen, cyano, hydroxyl, amino and mercapto;
the catalyst is selected from protonic acid or Lewis acid;
R 1 、R 1 ’、R 1 "are each independently selected from hydrogen or a hydroxy protecting group;
2. The method of claim 1, wherein R 2 、R 3 、R 4 、R 5 Each independently selected from hydrogen and C 1 -C 6 Alkyl radical, C 1 -C 6 Alkoxy radical, C 1 -C 6 Alkylthio, halogen, cyano, hydroxy, amino and mercapto.
3. The method of claim 1, wherein R 2 ’、R 3 ’、R 4 ’、R 5 ' each is independently selected from hydrogen, C 1 -C 6 Alkyl radical, C 1 -C 6 Alkoxy radical, C 1 -C 6 Alkylthio, halogen, cyano, hydroxy, amino and mercapto.
4. The process according to any one of claims 1 to 3, wherein the benzoquinone-like compound is selected from the group consisting of DDQ; NQ; TCQ; TBQ; TFQ; BQ; 3, 6-di-tert-butyl-4, 5-dimethoxy-1, 2-benzoquinone; 3, 6-di-tert-butyl-4, 5-dichloro-1, 2-benzoquinone; 3, 6-di-tert-butyl-4, 5-difluoro-1, 2-benzoquinone; 3,4,5, 6-tetramethyl-1, 2-benzoquinone; 3,4,5, 6-tetraethyl-1, 2-benzoquinone; 3,4, 6-trichloro-5-methyl-1, 2-benzoquinone; 3, 6-diphenyl-4, 5-dimethoxy-1, 2-benzoquinone; 3, 6-dichloro-4, 5-dimethoxy-1, 2-benzoquinone; 3, 6-dimethyl-4, 5-dimorpholinyl-1, 2-benzoquinone; 3, 5-di-tert-butyl-1, 2-benzoquinone; 4, 5-dimethoxy-1, 2-benzoquinone; 4, 5-diethoxy-1, 2-benzoquinone; 3, 6-di-tert-butyl-1, 2-benzoquinone; 4-tert-butyl-1, 2-benzoquinone; 3, 5-dimethyl-1, 2-benzoquinone; 3, 5-di-tert-butyl-6-chloro-1, 2-benzoquinone; 4-phenylnaphthalene-1, 2-dione; 3-phenylnaphthalene-1, 2-dione; 2, 3-dimethoxy-1, 4 benzoquinone; 2, 6-diisopropyl-1, 4 benzoquinone; 2,3,5, 6-tetraiodo-1, 4 benzoquinone; 2, 5-dimethoxy-1, 4 benzoquinone; 2, 3-dimethoxy-1, 4 benzoquinone; 2, 3-dichloro-1, 4-benzoquinone; 2, 5-diethoxy-1, 4-benzoquinone; 2-phenyl-1, 4-naphthoquinone; 2-phenyl-anthraquinone; 2, 5-dibromo-3, 6-dimethoxy-1, 4-benzoquinone; 2, 3-dibromo-5, 6-dicyano-1, 4-benzoquinone; 2, 5-dichloro-3, 6-dicyano-1, 4-benzoquinone; 2, 6-dichloro-3, 5-dicyano-1, 4-benzoquinone; and 2, 3-diiodo-5, 6-dicyano-1, 4-benzoquinone, preferably 3, 5-di-tert-butyl-1, 2-benzoquinone.
5. The method according to any one of claims 1 to 4, wherein R is 1 、R 1 ’、R 1 "are each independently selected from hydrogen, methoxymethyl, methoxyethoxymethyl, allyl or p-methoxybenzyl, preferably R 1 、R 1 ’、R 1 "is hydrogen, methoxymethyl, methoxyethoxymethyl or p-methoxybenzyl.
6. The preparation method according to any one of claims 1 to 5, wherein the catalyst is selected from hydrochloric acid, acetic acid, sulfuric acid, nitric acid, phosphoric acid, oxalic acid, citric acid, benzenesulfonic acid, substituted benzenesulfonic acid, benzoic acid, substituted benzoic acid, trifluoroacetic acid, trifluoromethanesulfonic acid, aluminum chloride, iron chloride, boron trifluoride, antimony pentafluoride, niobium pentachloride, zinc chloride, copper chloride, zinc sulfate, zinc trifluoromethanesulfonate, ytterbium trifluoromethanesulfonate, yttrium trifluoromethanesulfonate, copper trifluoromethanesulfonate or TMSOTf, preferably aluminum chloride, iron chloride, boron trifluoride, antimony pentafluoride, niobium pentachloride, zinc chloride, copper chloride, zinc sulfate, zinc trifluoromethanesulfonate, ytterbium trifluoromethanesulfonate, yttrium trifluoromethanesulfonate, copper trifluoromethanesulfonate or TMSOTf, more preferably zinc chloride.
7. The process according to any one of claims 1 to 6, wherein the molar ratio of the compound of formula (II) to the benzoquinone compound is from 2:1 to 1:20, preferably from 1:1 to 1: 10.
8. The production process according to any one of claims 1 to 7, wherein the molar ratio of the compound represented by the formula (II) to the catalyst is from 1:0.1 to 1:1.5, preferably from 1:0.5 to 1:1.
9. The process according to any one of claims 1 to 8, wherein the process further comprises the step of reacting the compound of formula (IIA) with an acid, preferably hydrochloric acid, acetic acid, sulfuric acid, nitric acid, phosphoric acid, oxalic acid, citric acid, benzenesulfonic acid, substituted benzenesulfonic acid, benzoic acid, substituted benzoic acid, trifluoroacetic acid or trifluoromethanesulfonic acid, preferably in a molar ratio of the compound of formula (IIA) to the acid of from 1:1 to 1: 100.
10. A preparation method of a compound shown as a formula (I) comprises the step of reacting a compound shown as a formula (II) in the presence of a benzoquinone compound and a catalyst to prepare an intermediate compound, and also comprises the step of reacting the intermediate compound with an acid,
wherein,
R 2 、R 3 、R 4 、R 5 Each independently selected from hydrogen and C 1 -C 6 Alkyl, 6-to 10-membered aryl, C 1 -C 6 Alkoxy radical, C 1 -C 6 Alkylthio, halogen, cyano, hydroxy, amino and mercapto;
R 2 ’、R 3 ’、R 4 ’、R 5 ' each is independently selected from hydrogen, C 1 -C 6 Alkyl, 6-to 10-membered aryl, C 1 -C 6 Alkoxy radical, C 1 -C 6 Alkylthio, halogen, cyano, hydroxy, amino and mercapto;
the catalyst is selected from protonic acid or Lewis acid;
R 1 、R 1 ' are each independently selected from hydrogen or a hydroxy protecting group.
11. A process for the preparation of ecteinascidin compounds comprising the process for the preparation of a compound of formula (I) as claimed in any one of claims 1 to 10.
12. The method according to claim 11, wherein the ecteinascidin-based compound is selected from one or more of ecteinascidin 729, trabectedin, ecteinascidin 745, ecteinascidin 759A, ecteinascidin 759B and ecteinascidin 770.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202110088058 | 2021-01-22 | ||
CN2021100880586 | 2021-01-22 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN114805398A true CN114805398A (en) | 2022-07-29 |
Family
ID=82527160
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202210038224.6A Pending CN114805398A (en) | 2021-01-22 | 2022-01-13 | Preparation method of ecteinascidin compound |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN114805398A (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115677728A (en) * | 2022-11-02 | 2023-02-03 | 成都科岭源医药技术有限公司 | Preparation method of ecteinascidin compound intermediate |
-
2022
- 2022-01-13 CN CN202210038224.6A patent/CN114805398A/en active Pending
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115677728A (en) * | 2022-11-02 | 2023-02-03 | 成都科岭源医药技术有限公司 | Preparation method of ecteinascidin compound intermediate |
WO2024093091A1 (en) * | 2022-11-02 | 2024-05-10 | 成都科岭源医药技术有限公司 | Preparation method for intermediate of ecteinascidin compound |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9539287B2 (en) | Triterpenoids and compositions containing the same | |
US8981144B2 (en) | Method for synthesizing 2-cyano-3,12-dioxoolean-1, 9(11)-dien-28-oic acid methyl ester and derivatives thereof | |
BR112014008196B1 (en) | process for the preparation of a compound of the formula | |
CN114805398A (en) | Preparation method of ecteinascidin compound | |
EP2147923A1 (en) | Method for producing aromatic compound | |
US4122092A (en) | Total synthesis of (±)-picropodophyllone and (±)-4'-demethylpicropodophyllone | |
Fuhrhop et al. | Dimers of 5, 15-dioxoporphodimethenes with direct links between methine bridge carbon atoms | |
Liang et al. | Paclitaxel analogs modified in ring C: synthesis and biological evaluation | |
Sharma et al. | Alkoxycarbonylation of quinones. A route to naphthacene quinones. Reversibility in homolytic substitution | |
US9296774B2 (en) | Halogenated dideoxy sugar derivates, preparation method and application thereof | |
Gupta et al. | Phototransformations of some 3-alkoxy-2-styrylchromones: type II cyclisations of 1, 4-and 1, 6-biradicals | |
EP2825547B1 (en) | Combined synthesis route for etonogestrel and desogestrel | |
EP0231671A1 (en) | Gonatriene derivatives and process for preparing them | |
Tuleen et al. | Reactions of methyl. beta.-naphthyl sulfides with N-halo-succinimides | |
CN108250055B (en) | Preparation method of pyruvylgeranyl pyrophosphate intermediate | |
CN113999241B (en) | Method for synthesizing cephalotaxine intermediate | |
Glushkov et al. | Synthesis of 2, 5-cyclohexadien-4-one-spiro-3'-(2'-R-5', 5'-dimethyl-1'-pyrrolines) by the Ritter reaction | |
EP3925948B1 (en) | Intermediate of eribulin, synthesis method therefor and use thereof | |
JPS59116246A (en) | Novel anthracyclinone and its preparation | |
JP4903956B2 (en) | Process for producing 7-oxabicyclo [2.2.1] hept-5-ene-2-carboxylic acid derivative | |
CA1127147A (en) | STEROIDAL [16.alpha.,17-.beta.]BENZODIOXINS | |
Baldovino‐Pantaleón et al. | Novel synthesis of new 1, 2, 4‐trithioles by reductive coupling of benzoyldithioacetic acid derivatives mediated by Sml2 | |
Faraz et al. | A short and elegant synthetic approach for 9-substituted tetrahydro coumestan derivatives and synthesis of some naturally occurring coumestan derivatives | |
Corelli et al. | Synthesis of bicyclo [9.3. 1] pentadecane derivatives, interesting intermediates for the preparation of taxuspine U and related diterpenoids | |
ONDA et al. | Heterocycles. IV. Photolyses of the 4-Arylacetylated 1, 2-Dihydroisoquinoline, Isocarbostyril and Its Enol Acetates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
WD01 | Invention patent application deemed withdrawn after publication |
Application publication date: 20220729 |
|
WD01 | Invention patent application deemed withdrawn after publication |